Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data

24 September 2026 · By · Wire by Fusion42

Published

24 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 24 September 2026 · Fusion42 review

Kyverna Therapeutics' CAR T therapy mivocabtagene autoleucel (miv-cel) showed durable improvement in patient mobility and a favorable safety profile in stiff person syndrome, supporting their planned FDA priority review filing this year.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You are facing the first real chance for CAR T in autoimmune diseases as Kyverna advances FDA review with positive durable data. This opens a new market for cell therapies you can target or compete in before others follow.

◆ Coverage

2 sources · 24 Sep 2026

◆ Related on Wire

◆ Topics

Biotechcar-tautoimmunefda-priority-reviewbiotechclinical-trial